About this episode
In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study.
Key References:
- QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/
- QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/
- ASH Abstract Data on impact of # of Consolidation Cycles: https://ash.confex.com/ash/2020/webprogram/Paper138498.html
- Hovon 97 (Azacitidine SQ maintenance): https://pubmed.ncbi.nlm.nih.gov/30630862/
- Mayer, et al. NEJM. 1994. (CALGB HiDAC consolidation): https://pubmed.ncbi.nlm.nih.gov/8078551/
- Büchner, et al. JCO. 1985: https://pubmed.ncbi.nlm.nih.gov/3906048/
Get every episode summarized
Each time WolverHeme Happy Hour publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from WolverHeme Happy Hour
VAR Review with Dr. Bixby: Reversing the Call on MPAL
WolverHeme Happy Hour
Jul 1, 20261:06:57pending
Bispecifics ate CAR-T's lunch: a multiple myeloma debate
WolverHeme Happy Hour
Jun 11, 202656:28pending
Episode 47: Cult-Like Thinking in BMT
WolverHeme Happy Hour
Jun 4, 202645:23pending
Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology
WolverHeme Happy Hour
Apr 13, 20261:01:29failed